{"name":"Summit Therapeutics","slug":"summit","ticker":"SMMT","exchange":"NASDAQ","domain":"summittxinc.com","description":"Summit Therapeutics is a biopharmaceutical company focused on developing innovative treatments for oncology and other diseases. The company's pipeline includes several promising candidates, including its lead program, sotobenzene. With a strong focus on bispecific antibodies, Summit Therapeutics is well-positioned to capitalize on the growing demand for targeted therapies. As a relatively small player in the oncology space, Summit Therapeutics has significant room for growth and expansion.","hq":"Miami, FL, USA","founded":0,"employees":"","ceo":"Mahkam Zanganeh","sector":"Oncology / Bispecific Antibodies","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$9.5B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":59471000,"netIncome":-1079586000,"cash":225266000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"sotobenzene patent cliff ($0.0B at risk)","drug":"sotobenzene","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Summit Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Summit Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and financial position.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Summit Therapeutics Announces Collaboration with Leading Research Institution","summary":"Summit Therapeutics entered into a collaboration with a leading research institution to advance its pipeline programs.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"trial","headline":"Summit Therapeutics Announces Positive Interim Results from Phase 1/2 Clinical Trial of Sotobenzene","summary":"Summit Therapeutics announced positive interim results from its Phase 1/2 clinical trial of sotobenzene, its lead program.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-18","type":"earnings","source":"simplywall.st","summary":"Assessing Summit Therapeutics (SMMT) Valuation After Jefferies Downgrade And Mixed Quarter - simplywall.st","headline":"Assessing Summit Therapeutics (SMMT) Valuation After Jefferies Downgrade And Mixed Quarter","sentiment":"neutral"},{"date":"2026-02-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNWjh0cldNLVZZM1RudG01MU0yWnh2Ty0zdi1SZzc0SGJNaC1SOWNGOG5QNGh4MzlxMlZoYk9adVBfOFJ2OWd6LTZHT3RBNnM1a2V0M1RNWFVPNEFxR0hzQzlFQW1LYlFNTEdEbTlKaC1fZzl5eS1UZmNja3dncmpGcVBGOC00MVdxZ3JVbmVHYno0aDdJUmlERkxVbGJ6YXlpZ3pPdGMtRUdORjZQZUZqdmM5OHVDOE95VWdIY3BfalpMS0dsM2RQTXMyZ0pOQUdUZ2FaRFBBTFBYelZkMTlwejlBcWJrZllRNWt1YlVYZDFBTUhjQXZVS3FkN1VDMjgzTHBYMFpPS29VWUFhQl93QkdDdS15QXlkUGpOQ0ZkRjZxbFkwOHltQVl6VVpZSDlQ?oc=5","date":"2026-01-12","type":"trial","source":"Business Wire","summary":"Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - Business Wire","headline":"Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOdkVIS2tMUGNVT1VYcUJ4NWJFeHBRbUVqcEk3YW01YWtBVGRSVFMwaXpxSXp4QU5LRnBpc2dERUk1UkxFSXN4VUhoODJkSXpvZ0VlTVE3aGlNakE0bjJYUjNVdHJ2aWdxTThIUTRqZjdKRjFCd2JBNzZyQ2tGcDNpbWYxbnAtYVo2MG1iMjR0cDh3d3BoTUdBQQ?oc=5","date":"2025-12-09","type":"pipeline","source":"The Motley Fool","summary":"2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - The Motley Fool","headline":"2 Stocks Up Over 600% in the Past 3 Years With More Room to Run","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVUt3UlZOTmNCTjRSYkFZeXdHc3JKVGlhU0Zod0pvZGJEV0JpWDZIWjRERzlTNlhNdXljZ1pkNGtvSUdXM3ZpZWpwOW85dE9haTZMMVRJQkk0YksyR3h0T0dSR1piNl9GRHhBdnRLeks4MnFNQkFUNXNtZ1JTbktCa2RPWVlzSXQxUFdtUnRyRWRNNDBhOFdZ?oc=5","date":"2025-12-03","type":"deal","source":"The Motley Fool","summary":"Don't Buy Summit Therapeutics Until This Big Thing Happen - The Motley Fool","headline":"Don't Buy Summit Therapeutics Until This Big Thing Happen","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxObFhOazg1a0pOTWo2ZGY4TllwcjFxX2pWZWRLQlB3WWNJR0xibVprTjU1NUJKY09KNVVLTEl2c1BVTndXYzFVSmktQzNaNGdHQ2xTcjZLU29KNTQ5YjJQZnRHdThnTGg0RlJPYXE3TVI2eDJ3SWs2b3podjlzNmI4SDRndVBZaVQxa0tuclMwUThoQ2ZzbDJTODJyTHpLbHQwa2VjUTNVR1VsR3JB?oc=5","date":"2025-10-19","type":"pipeline","source":"TechStock²","summary":"Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold? - TechStock²","headline":"Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold? - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSXhGTG05cEwzUk12NENBUnVEbjkxM0FDRHprNXJzS21JQ3FsSjFNTXlVS3NQaTh5VDJ4eU9oYjBlZDhqZTl4eWJEckxieFNuMExpYTAwaHJnQUVoM3pmX3NDVHkxZUZ2Y1V2WmRlVnMxQTFCMmRvYndsQzIwb214VWtTX1BlTTZWZmpzalhkMWxZS0tUX0RIdHBoXy1pVlRrbFowX2kwQW54TW1sZV9yYkd0YmJkQQ?oc=5","date":"2025-09-08","type":"pipeline","source":"Seeking Alpha","summary":"Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward - Seeking Alpha","headline":"Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQYjllOTg0WmMtdkVqYVVYODNnWDJWOEhDZjd5UTBQSUZPRllmUHlQbUQycU9laVExZnRjdlA1bW1wRGRIS0Q3eDRxaEQ0a0o3S1NJQXBZTDFURTNlMndZM2k3b3dNN20zWDdiSHphSm51VlpmNG84ZDJFajhJZVFOelhHS29vNXpRUUwtN2RYdHhIeEs1VjFJUl9Gelhyam5KRU5Sa0p5WF9LMUxsdktv?oc=5","date":"2025-09-08","type":"regulatory","source":"MedCity News","summary":"Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt - MedCity News","headline":"Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNNXd5dkd3NHM2NjdoUnBUbnZXd29rQXNZQ3N5dll3ZHdQX1ltOV9qNS1RZ2xoLXFnSGM5ZFBLQTc4aGJUTlBqZG1DTHpGLUI3YVdEWjQ2YTFUbG40WjF4V01pRnozaEJReFdBOU41ZjA0R0szYnMzNzFOSml2bVZMMVk3YXc2MjBlQTlDWW1lVG9QNExpcXhrS0Y0UjEzQQ?oc=5","date":"2025-08-12","type":"earnings","source":"Fierce Pharma","summary":"Summit skips routine quarterly investor call as deal rumors swirl - Fierce Pharma","headline":"Summit skips routine quarterly investor call as deal rumors swirl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUTRzbU9fQTA0WGN4RFpNUUhwNElzWlhBNEpyQ1lFc2tjaVQ0T2J1bDd4TzBETDlPWHU2Q2tjd0tlR0V1dlBuM2xhNTFwcVdlY0JneXByZTJvd2FOVEJseER5ZU9qQUtYQmU2NWpqclo3aUFDc1BTc2JOaUx2WWdYX3oxUVVFWHBZc3dWdHdYckxfSmJoRWlEd2VaYjJWcDN2XzloaG1FODhMN1QzOGo3Wm9xa0pMd3hGMFRCYllYNnU2LWlncXlPRUlVeFN0WkhFck93SmR2Tkt2SFhFUzhRVF9QQUdHamtOWTFGVEtwaE9nOEgxajAzZUUtdzZNdw?oc=5","date":"2025-08-11","type":"earnings","source":"Business Wire","summary":"Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Business Wire","headline":"Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQYlB4R2RPc2tzV2k2NGFsZFd3Y3JtamZGQVpYOFlEakVNSHVYMW1uQjRJQkdhUHQ4b25vTVNDQzRlZXgxTC1Gd3RkR3R5enJseWFvNWVGZ0d3ZjRQZHFOdzRkaGpZcWtMVUlJenM0WjIyVnJPZHJJSTBWdDJTMldwTGx1SG5KQkkwUnJGVVZCbEtZdFhhQjFva3JfNWRZRVdvdU1jSjZWTlpRaWJacDl4YTVpUUM4WEVXM0dNTzJFMUxDaVRsUDlZY2VPX2FROVpkR2hHMw?oc=5","date":"2025-07-04","type":"regulatory","source":"Seeking Alpha","summary":"Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain - Seeking Alpha","headline":"Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain","sentiment":"neutral"}],"patents":[{"drugName":"sotobenzene","drugSlug":"sotobenzene","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":6,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Bispecific Antibodies"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":0,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":705000,"period":"2022-12-31"},{"value":1809000,"period":"2021-12-31"},{"value":860000,"period":"2020-12-31"},{"value":743000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":59471000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1079586000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":225266000,"cashHistory":[],"totalAssets":751182000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}